Showing results (191-200 of 204) with videos related to

Sort By:
Pageof 21
JAMA|July 10, 2023
Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical TrialJane A O'Halloran, Emily R Ko, Kevin J Anstrom, et al.
The Lancet. Infectious Diseases|June 20, 2025
Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b studyJohan A Maertens, George R Thompson, Andrej Spec, et al.
JAMA|December 18, 2024
2024 Update of the RECOVER-Adult Long COVID Research IndexLinda N Geng, Kristine M Erlandson, Mady Hornig, et al.
Nature Communications|November 17, 2025
Long COVID trajectories in the prospectively followed RECOVER-Adult US cohortTanayott Thaweethai, Sarah E Donohue, Jeffrey N Martin, et al.
JAMA Network Open|September 25, 2025
Olfactory Dysfunction After SARS-CoV-2 Infection in the RECOVER Adult CohortLeora I Horwitz, Jacqueline H Becker, Weixing Huang, et al.
JACC. Advances|June 22, 2026
Sustained Reduction in Cardiopulmonary Fitness in Long COVID: A Report from the RECOVER-adult Cohort StudyJulia Moore Vogel, Trevor Jenkins, Marta Cerda, et al.
The New England Journal of Medicine|December 11, 2020
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19Andre C Kalil, Thomas F Patterson, Aneesh K Mehta, et al.
The Lancet. Respiratory Medicine|October 21, 2021
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trialAndre C Kalil, Aneesh K Mehta, Thomas F Patterson, et al.
Annals of Internal Medicine|August 12, 2024
Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER CohortKristine M Erlandson, Linda N Geng, Caitlin A Selvaggi, et al.
The Lancet. Respiratory Medicine|May 26, 2022
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trialCameron R Wolfe, Kay M Tomashek, Thomas F Patterson, et al.
Pageof 21